Latest news

PCI Biotech receives positive opinion for Orphan Drug Designation of fimaporfin for treatment of cholangiocarcinoma in EU

Posted on Jul 26, 2016

Oslo, 25 July 2016 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that it has received a positive opinion from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) for its lead product candidate, fimaporfin, for the treatment of cholangiocarcinoma (bile duct cancer). COMP’s positive opinion is subject to […]

Curida and PCI Biotech have entered into a manufacturing agreement

Posted on Jul 1, 2016

Oslo, July 1, 2016 – The pharmaceutical Contract Development and Manufacturing Organization Curida has entered into a manufacturing agreement with the Norwegian biotech company PCI Biotech. Curida will manufacture Amphinex, the lead product candidate from PCI Biotech. Amphinex is currently undergoing international clinical trials for bile duct cancer, a rare cancer disease with a high […]

Pre-clinical research collaboration agreement with top-10 large pharma company extended

Posted on May 26, 2016

Oslo, May 26, 2016 – PCI Biotech reported today that the existing research collaboration agreement signed in September 2015 with an undisclosed top-10 large pharma company has been extended until the end of 2016. The aim of the research collaboration is to evaluate the synergistic effects of both parties’ technology platforms, to determine whether PCI […]